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FIG. 2A
Impact of Put-BSA Conjugate
on Polyamine Uptake
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POLYAMINE-POLYAMINE AND
POLYAMINE-PROTEIN TRANSPORT
INHIBITOR CONJUGATES AND THEIR USE
AS PHARMACEUTICALS AND IN
RESEARCH RELATING TO POLYAMINE
TRANSPORT

Seiler et al., Brain Res., 22, 81 (1970)). Enhanced uptake of

FIELD OF THE INVENTION

The present invention is directed to polymeric conjugates
of substances which are normally actively transported into
cells or protein or polypeptide conjugates of such nonnally
transported substances and the use thereof to inhibit uptake
of such normally transported substances. The present inven
tion is more particularly directed to polymeric conjugates of

1‘*C-labeled polyarnines by tissues with depleted polyamine
stores has repeatedly been observed (Chaney et al., Life Sci.,
32, 1237 (1983); Huston et al., Cancer Res., 44, 1034

(1984)).
Recently, much research has been undertaken to charac
terize and understand the particular transporters which con
trol polyamine uptake in mammalian cells. Early work on
polyamine transport related to bacteria and other microbia
10 and is reviewed in Tabor et al., Pharmac. Rev, 16, 245

(1964) and Bachrach, “Function of Naturally Occurring
Polyamines,” pp. 51-52, Academic Press, NY. (1973).
Other papers describing polyamine transport in speci?c
microbia are also available in the literature (Davis et al.,

Arch. Biochem. Biophy, 267,479 (1988) and Kashiwagi et
al., J. East, 165, 972 (1986)).
Polyamine uptake systems in mammalian cells resemble
the uptake systems of amino acids. Accordingly, most
researchers studying polyamine transport have used research

polyamines, and conjugates of polyarnines and proteins or
polypeptides and the use thereof to inhibit the cellular

uptake of polyarnines.
BACKGROUND OF THE INVENTION

20

The endogenous polyamines, in particular, putrescine

(l,4~butanediamine), spermidine (N-[3-aminopropyl]-1,4
diarninobutane) and spermine (N,N‘-bis-[3-aminopropyl]-1,
4-butane-diamine) have been the subject of increasing
research, due to the growing appreciation of their physi—

25

strategies which have had prior success in characterizing
amino acid uptake.
To date there still exists no complete understanding of
polyamine transport systems in mammalian cell lines. How
ever, from what is disclosed in the literature, it appears that
polyamine transport is energy and temperature dependent,
and saturable. Therefore, it seems that it is a carrier-medi

ological importance. These polyarnines have regulatory

ated transport system. An exception is polyamine transport

roles in tissue growth and interact with nucleic acids, as well
as exhibiting a variety of eifects upon macromolecular

into perfused rabbit lung or lung slices which appears not to
be energy dependent or Na‘“ activated, suggesting that

synthesis, expression and metabolism (Tabor et al., Ann.
Rev. Biochem, 30, 597 (1961); Janne et al., Biochem.

30

Biophys. Acta, 473,241, (1978); and Tabor et al., Ann. Rev.

Biochem, 45,285 (1976)).
Accounts on the biochemistry, regulation and potential
functions of polyarnines may be found in recent review

35

articles (Tabor et al., Ann. Rev. Biochem, 53,749 (1984);
Pegg et al., Ann. J. PhysioL, 243, C212 (1982); Pegg,
Biochem J., 234, 249 (1986); Seiler et al., Acza Biochem.
Biophys. Hung, 23, 1 (1988); and, Seiler et a1, Int. J.
Biochem, 22, 211, (1990)) from which most of this back
ground discussion is excerpted.
Polyarnine homeostasis and adjustment of the intracellu~
lar concentrations to physiological requirements are regu~
lated by both synthetic and catabolic reactions. De novo

biosynthesis can in principle be substituted by polyamine

(Italy), Abst. p. 67 (1988). Most cells appear to have a single

shown by competitive studies. However, some cells appear
to have more than one pathway for polyamine uptake
wherein each transporter comprises a di?ferent at?nity for
45

diacetylspermine may also ful?ll regulatory requirements.
The actual signals which control polyamine release are not
known. However, there exists strong evidence in the scien

Science, 221,673 (1983)) and normal but rapidly proliferat
ing cells (Janne et al., Acta Chem. Scand, 20, 1174 (1966);

putrescine, spermidine and spermine (Kumagai et al., Am. J.
Phys., 254, G81 (1988); Minchin et al., Int’l. Symp.
Polyamines Biochem. Clin. Res,, Sorrento (Italy),Abst. p. 67
(1988); Byers et al., Am. J. PhysioL, 252, C663 (1987);
Feige et al., Biochem. Biophys. Acta, 846, 93 (1985); and De
Srnedt et al., Biochem. Biophys. Acza, 1012, 171 (1989)).
The a?inity for the carrier increases from putrescine to
spermidine and spermine with published Km values in the
low M range. Polyamine transport is observed in the
absence of sodium; however, the increase of sodium to

55

physiological concentrations (116 mM) usually increases the
transport rate by 60%. Dissipation of the sodium gradient by
ionophores has been shown to inhibit the sodium-dependent

portion of polyamine uptake.

col., 65, 2034 (1987)).
In vivo studies involving the metabolism of labeled
polyarnines have shown that polyarnines may be taken up by
tissues from the circulation. It is further well known that
some tissues exhibit a high demand for polyamines.
Examples of such tissues include the prostate (Clark et al.,
J. Nucl. Med, 16, 337 (1975)), tumor cells (Volkow et al.,

and energy-dependent (Rannels et a1).
Available evidence suggests that macromolecular synthe
sis of RNA and prornins is required to adapt polyamine
transport to enhanced polyamine requirement (Martin et al.,
Inl’l. Symp. Polyamines in Biochem. Clin. Res., Sorrento
transporter for putrescine, spermidine and spermine as

transport from the environment.
In cells lacking amine oxidases which oxidatively deami‘
nate polyarnines, the release of intracellular polyarnines is
essential for the regulation of polyamine cellular concentra
tions. Currently available evidence suggests that Nl-Nz

ti?c literature that the proportion of N‘-acetylspermine and
N'-acetylspern1idine which remains intracellular and which
is oxidatively cleaved into spermidine and putrescine is
controlled by outward transport (Seiler, J. Physiol. Pharma

polyamine uptake into the lungs of this species may instead
occur via diffusion (Rao et al., Biochem. Biophys. Acta, 966,
22 (1988)) rather than an active carrier system. Polyamine
uptake in lungs of other species, including rats, is saturable

While high a?inity sodium-activated transport is usually
60

observed, some cell types exhibit sodium-independent

polyamine uptake. For example, in LLC-PKl renal epithe
lial cells both the sodium-activated and the sodium-inde

pendent transport systems were saturable. By contrast, in
adrenocortical cells the sodium independent transport sys
65

tem was not saturable and preferentially transported sper—

mine (Feige et al., Biochem. Biophys. Acta, 846, 93 (1985)).
Activation of polyamine transport into mammalian cells

5,456,908
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by thiols (glutathione, dithiothreitol) and inhibition by thiol

DFMO treatment (Ask et al., Cancer Lett., 66, 29 (1992)).
The polyamine uptake system has been implicated in the
uptake of other drugs as well. For example, paraquat (N,N‘

reagents (p-chloromercuribenzene sulfonate, N~ethylmale
imide) has been studied by many researchers. The results
obtained by these researchers suggest that the sodium
activated transporter requires thiol groups to maintain active
conformation.
The amino acid uptake pathways are generally regarded
as diiferent from polyarnine transporters systems. However,
a number of amino acids (asparagine, glutamine, serine,
alanine and ot-(methylarnino)isobutyric acid) stimulate at
0.5 mM concentration putrescine uptake into a neuroblas
toma cell line (Rinehart et al., J. Biol. Chem., 259, 4750

dimethyl-4,4'-dipyridylium) has been shown to inhibit the

uptake of MGBG, putrescine and spermidine, but with no
apparent eifect on spermine uptake (Smith et al., Biochem.

Pharmac., 30, 1053 (1981)).
Also, some researchers have attempted to design cyto
toxic drug conjugates which are similar in structure to
10

recently synthesized a series of 2- and S-nitroimidazole

polyarnine conjugates which were apparently transported by
the polyarnine transport system. Of the compounds tested,

(1984)) and that some basic amino acids exhibit a very weak

inhibitory effect on polyamine uptake.

the 2-nitroimidazole-po1yamine conjugates were the most

The polyamine transporter does not appear to be speci?c

potent inhibitors of spermidine uptake (Holley et a1, Bio
chem. Pharmacol. 43,763, (1992)).
Also, several bipyridinium, tetrapyridinium and hexapy

for putrescine, spermidine or spermine. Therefore, it is likely
that polyamine analogs are transported by the same system.
Some researchers have compared a series of homologous

ridinium quaternary salts have been found to be potent

diamines and triarnines in relation to their ability to inhibit

competitively the uptake of labelled putrescine, spermidine

20

and spermine by L1 210 leukemia cells. 1,7-Heptene diarnine
followed by l,8~octanediamine and 1,6-hexanediamine were

between the positively charged nitrogen atoms of spermi
dine, presumably in its most stable all-trans con?guration.
(Gordon-Smith et al., Biochem. Pharmacol, 32, 3701,

with the potency of inhibition being apparently directly

Biochem. J., 262, 391 (1989).
25

example, the cationic peptide melittin and another calmodu

lin antagonist, 1.3~dihydroxy-l-(4-methyl)- 4H,6H-pyrrolo

[1,2-9][4,l]-benzoxazepin-4-y1)methyl]-4-piperidinyl]-2H
30

benzimidazol- 2-one (CG 59373B) inhibits putrescine
uptake into human prostate cells. Tri?uoropiperazine, a
calmodulin antagonist and protein kinase C inhibitor also
inhibits polyamine uptake as does the protein kinase C

inhibitor H7 (l-(5-isoquinolinylsulfonyl)-2-methyl-pipera

The primary amine groups of the polyamines seem to be
35

petitively inhibit uptake. Also, substituents (F, Cl, OH, CH3)

zine). Also, treatment of leukemia cells with phorbyl esters
activates proteinase kinase C and has been shown to enhance
spermidine uptake into murine leukemic cells. It therefore
appears that protein kinase C may play a role in polyamine

transport.

in the last two positions of the carbon chain of putrescine

reduce polyarnine uptake.

Some inhibitors of polyamine uptake have been discov
ered which are structurally unrelated to polyamines. For

(1983)).
essential for uptake. For example, N-alkyl substituents on
the terminal arrrino groups of putrescine, spermidine or
spermine decrease the ability of these compounds to com

inhibitors of putrescine uptake into B16 melanoma cells
which have previously treated with di?uoromethylornithine,
related to the number of quaternary centers (Minchin et al.,

most potent among the diarrrines, while triarnines were

generally more effective as uptake competitors. Maximum
inhibition was achieved using amines having comparable
chain lengths to spermine and spermidine. This is consistent
with the understanding in the art that the recognition site of
the polyarnine transporter contains at least three negatively
charged groups in a distance corresponding to the distance

endogenous polyamines so that they are transported by the
polyarnine transport system. For example, Holley et a1.

40

Various factors are believed to affect the uptake of

Methylglyoxal-bis(guanylhydrazone) (MGBG), an anti
leukemic drug which inhibits S-adenosylmethionine decar

polyamines into mammalian cells including (i) availability
of polyamines in vivo, (ii) intracellular polyamines, (iii) the

boxylase and which exhibits a structure highly similar to

sialic acid coating on the cell membrane, and (iv) the growth
state of the particular cells.
The availability of polyamines in the circulation is
believed to be important in polyamine transport. Putrescine
and spermine blood concentrations are low in comparison to

spermidine shares the polyamine transport system. The
potent cytotoxicity of this compound thereby afforded

45

researchers a selection method for identifying Chinese ham
ster ovary cells incapable of MGBG and polyamine trans

port (Mandel et al., J. Cell. Physiol, 97, 335 (1978). Genetic

sperrrridine (Claverie et al., Anticancer Res., 7, 765, (1987)).
This is surprising given that the electrostatic binding of
spermine to negatively charged groups is higher than for
spermidine and putrescine. Accordingly, one would expect
the concentration of free spermine to be extremely low,

studies indicate that more than one gene locus is involved in

MGBG uptake by these cells (Heaton et al., J. Cell. Physiol,
136, 133 (1988)).
Also, it is believed that such polyamine transport mutants
should play a major role in identifying genes involved in

polyamine transport, for studying the regulation of transport,
and for studying the role of polyamine transport in prolif

particularly in light of the fact that red blood cells have a
55

erating cells and in some related disease conditions such as
cancer.

For example, Ask et al. recently studied increased survival
of Ll2l0 leukemic mice by preventing utilization of extra
cellular polyarnines using an Ll210 leukemic cell line

The level of intracellular polyamines is also believed to
60

polyamines is probably involved in regulation of uptake.

uptake mutant cells exhibited a cure rate of 33% when

only had a two day increase in survival time after similar

a?ect polyamine uptake. Depletion of intracellular
polyamines has been found to generally enhance polyamine
uptake several-fold. As in the case of circulating
polyamines, the concentration of free intracellular

(Ll2lO-MGBG’) de?cient in polyamine transport. Their
results indicated that leukemic mice bearing the polyamine

polyamine synthesis was blocked by DFMO. By contrast,
rrrice having non-mutant polyarnine transport Ll2l0 cells

negative surface charge and e?iciently bind polyamines.
Further evidence of the importance of spermidine uptake is
the fact that the Vmax of spermidine is higher than that of
spermine, despite its lower a?inity to the transporter.

65

As noted above, the sialic acid coating on cell membranes
is believed to have some effects on polyamine transport. The

removal of N-acetylsialic acid from the surface of murine

5,456,908
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leukemia cells by incubation with neurarninidase enhances

spermidine uptake. Re-sialated cells regain normal transport

discussed supra, along with de novo polyamine synthesis,
cells are apparently capable of regulating and accumulating

rates (Khan et al., Biochem. Arch, 5, 161 (1989)). It is
believed by some researchers that the sialic cell surface

polyamines across their plasma membrane via an energy~

dependent transport system. Work by the present inventors

coating nonspeci?cally binds positively charged polyamines

and others suggests that most cells express at least two

via the carboxyl group of the sialic acid residues thereby
diminishing effective concentration of transport substances

pathways for polyamine uptake. The ?rst comprises a non

at the transporter site.

and the second comprises a pathway which is selective for

selective pathway for putrescine, spermidine and spermine

Polyamine transport is also believed to be important for
the ability of cells to adapt to changes in polyamine require
ments. Enhanced cell growth rates are usually accompanied

spermine and spermidine. Both pathways are markedly
increased when ODC activity is depressed, either by patho
logic changes or by treatment with DFMO, and are thereby

by both enhanced intracellular de novo synthesis and

able to compensate for decreased de novo polyamine syn
thesis. Because there exist no pharmacological agents which

enhanced uptake of polyamines.
Trophic stimuli, including hormones and growth factors,
have been observed to enhance polyamine transport rates

selectively inhibit polyamine transport, the suitability of this
15

pathway as a pharmacological target has as yet not been

(Pohjanpelto, J. Cell. Biol, 68, 512 (1976), DiPasquale et
al., Exp. Cell. Res., 116, 317 (1978)). In these studies

adequately established.

stimulation of human ?broblasts to cell proliferation by

inhibitors of polyamine transport have focused on

As discussed above, most previous attempts to design

serum or epidermal growth factor was followed by an

18~100 fold increase of ornithine decarboxylase activity.
Also, stimulation of mouse mammary glands with insulin
caused the increase of VW for spermidine and prevented
effects thereof (Kano et al., J. Biol. Chem, 251, 2795
(1976)). However, it is unknown whether the hormone

20

polyamine analogues with a few exceptions involving sev
eral calmodulin antagonists and protein kinase C inhibitors.
However, the previously examined molecules have either

lacked speci?city and/or exhibited unacceptable toxicity.
Thus, there still exists a substantial need in the art for

e?ective polyamine transport inhibitors which selectively

induced formation of the carrier or decreased carrier inac 25 inhibit the transport of speci?c polyamines while not exhib
iting unacceptable toxicity and while not a?ecting the trans—
tivation.

port of other transported substances. Also, there exists a
need in the art for a convenient and reproductive method for

Some studies have shown that transformed cells transport

polyamines better than their normal counterparts. However,

obtaining transport inhibitors of desired substances.

in at least one study involving EJZ-ras transfected cells
polyamine turnover was enhanced but transport rates

OBJECTS OF THE INVENTION

remained una?ected. In contrast, N-myc transfection
enhanced polyamine uptake with no affect on biosynthesis

It is an object of the invention to obviate the problems

(Chang et al., Biochem. Biophys. Res. Comm, 157, 164
(1988). Thus, there exists circumstantial evidence that
polyamine uptake and synthesis may be regulated by dif
ferent genes. Perhaps not unexpectedly, cells exhibiting

observed with previous transport substance inhibitors, e.g.,

non-speci?city and toxicity.
It is another object of the invention to provide novel
inhibitors of transport of substances normally actively trans

reduced growth rates have been observed to decrease

polyamine uptake. For example, cells approaching cell con
?uency because of high cell density decrease polyamine
uptake. Also, when cells are induced to diiferentiate and
therefore reduce their rate of proliferation, their demand for
polyamine has been found to diminish.
As discussed above, cellular concentrations of

polyamines are regulated by at least two important path

ported by cells which selectively inhibit the uptake of the
targeted substance into such cells, which comprise poly
40

polypeptide conjugated to the transported substance.
It is a further object of the invention to use such novel

transport inhibitors of targeted substances which comprise
polymers of transported substances or polypeptide or pro
45

ways. The ?rst, and best understood, involves de novo

biosynthesis. The rate of cellular polyamine synthesis is
governed by the activity of the enzyme ornithine decarboxy
lase (ODC) which catalyzes the conversion of the amino
acid ornithine to the diarnine putrescine. Putrescine, in turn,

50

is then convened sequentially to spermidine and spermine by
two other enzymes. The role of ODC in regulation of cell
polyamine contents and its potential suitability as a phar

macological target has been facilitated by the development
of DEMO, (ot-di?uoro-methylornithine), a highly selective

meric conjugates of the transported substance or a protein or

tein-transported substance conjugates in vitro to study the
role of the uptake of the targeted substance which is nor
mally actively transported on various cellular processes and
cell functions.
It is another object of the invention to administer such

novel transport inhibitors of normally transported sub
stances which comprise polymeric conjugates of transported
substances or protein or polypeptide-transported substance
conjugates in vivo to treat disease conditions which involve

55

transport of the particular transported substance.

and potent inhibitor of this enzyme. In some instances,

It is a speci?c object of the invention to provide novel

inhibition of ODC with DFMO is highly effective in deplet
ing cell polyamine cell contents and arresting cell prolifera

polyamine transport inhibitors which comprise polymers of

tion. However, in other instances the cells seem to use

compensatory pathways to maintain adequate polyamine
concentrations. Results of human clinical trials with DFMO

polyamines or polyamine-protein or protein conjugates
which selectively inhibit uptake of a targeted polyamine and
which do not exhibit undesirable toxicity.
It is another speci?c object of the invention to use novel

have, in general, been disappointing. Though the drug is

polyamine transport inhibitors which comprise polyamine

bene?cial in treating some non-neoplastic diseases (e.g.,
infectious conditions), its therapeutic ef?cacy in cancer

polymers or polyamine-protein or polypeptide conjugates
which selectively inhibit cellular uptake of targeted
polyamines in vitro to study the effect of the particular
targeted polyamine on cellular functions.

appears to be limited.
65
The reason for the poor results with DEMO is believed to

be attributable to the polyamine transport system of cells. As

It is yet another object of the invention to administer novel

5,456,908
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polyarnine transport inhibitors which comprise polyamine

the uptake of the drug. However, the subject transport

polymers or polyamine-protein or polypeptide conjugates
selectively inhibit the transport of targeted polyamines for
treating disorders wherein polyarnine transport is involved

inhibitors obtain a substantially diiferent function and result
in that they are not themselves transported into cells but

pharmaceutical compositions for treating disease conditions

instead selectively inhibit the transport system of the cell
which is responsible for uptake of the targeted transported
substance, e.g., a polyamine.
The ?rst class of transport inhibitory substances discov

relating to the transport of a targeted substance which

ered by the present inventors comprises polymeric conju

contain an effective amount of a novel inhibitor comprising

gates of the targeted transported substance wherein the
repeating units of the polymer comprise the particular tar
geted transported substance. These moieties may be directly

in the disease condition, e.g., cancer.

It is yet another object of the invention to provide novel

a polymer of the transported substance or a transported

substance-protein or polypeptide conjugate which selec
tively inhibits the cellular uptake of the targeted substance.
It is still another object of the invention to provide novel

pharmaceutical compositions for treating diseases wherein

linked or may be indirectly attached using known coupling
agents. It has been surprisingly discovered that polymers of
a targeted normally transported substance, e. g., a polyarnine

polyarnine uptake is involved in the disease condition com
prising adrninistering an e?fective amount of the subject

selectively block transport of the transported substance. By

novel polyarrrine transport inhibitors which comprise poly

selective it is meant that these polymers do not block
transport of non-targeted substances such as anrino acids and

such as putrescine, spermine or spernridine, may be used to

mers of polyamines or polyamine-protein or polypeptide

conjugates.

other normally transported substances. Also, these polymers
20

BRIEF DESCRIPTION OF THE INVENTION

previous transport inhibitor analogues and transported sub
stance-drug conjugates wherein the analogue or the drug

Previous attempts to design substances which inhibit the

cellular uptake of normally transported substances have in
general focused on synthesizing analogues of the normally

appear to act at the level of the cell membrane and do not
appear to enter the cells. This is in contradistinction to

25

transported substance. A case in point are the previously
synthesized polyarnine transport inhibitors which were in
general substances having structural similarity to trans

ported polyamines.
The rationale behind such an approach is that if the

particular analogue is similar enough in structure to the

nonnally transported substances it will be transported into

was apparently internalized by cells.
The second novel class of transport inhibitory substances
discovered by the present inventors to effectively and selec
tively inhibit transport of a targeted substance comprises
conjugates of the targeted transported substance and a pro
tein or polypeptide, preferably a protein or polypeptide that
does not exhibit undesirable toxicity. It has been surprisingly
discovered that when a normally transported substance is
conjugated to a protein, that the resulting conjugates are

the cell by the same cell transport system. Therefore, it

capable of selectively inhibiting the uptake of the speci?c

should provide for the competitive inhibition of uptake of
the targeted substance.
While this approach works in some instances, it is fraught

targeted substance. Also, as with the aforedescribed poly
meric conjugates, these transported substance-protein con
jugates apparently operate at the cell membrane and are not
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actively transported into cells. The targeted transported
substance may be directly coupled to the particular protein,

with many inherent problems. For one, it is sometimes

dif?cult to synthesize an analogue of the targeted transported

substance which is capable of being effectively transported

or may be attached by use of available coupling agents. In

into the cell by the same transport system and which

the preferred embodiment the targeted transported sub
stances will comprise endogenous transported polyamines,
e.g., putrescine, spermine and sperrnidine.

competitively inhibits the transport of the targeted sub
stance. Another problem is that the particular analogue, even
if transported, may exhibit undesirable toxicity which pre
vents its in vivo usage. Examples of such compounds
include antineoplastic agents such as methylglyoxalbis(gua
nylhydrazone) (MGBG) which while mimicking the struc
ture of endogenous polyamines and inhibiting the transport
thereof possess a high degree of toxicity.
Yet another problem with the design of effective inhibitors
involves designing substances which speci?cally inhibit the
uptake of a targeted substance while not inhibiting the
uptake of other non-targeted substances. This is essential for

Given the ability of these two classes of transport inhib
45

transport of a targeted substance involved in a particular
disease condition.

In the preferred embodiment the targeted transported
substances will comprise polyamines such as putrescine,

in vitro studies if one is to be able to elucidate the cellular

functions a?ected by the particular targeted substance. Also,

spermine and spermidine which are believed to be involved
55

it is important for in vivo usage in the use of such inhibitors
for treating disease conditions wherein one desires to inhibit
uptake of an undesirable targeted substance while not pre

venting uptake of other substances which may be essential
for well being.

iting substances to selectively inhibit transport of targeted
substances they comprise utility in vitro for studying the
cellular functions affected by a speci?c targeted transported
substance such as, e.g., a polyamine. Also, they comprise in
vivo utility as therapeutic agents for selectively blocking

in disorders involving unrestrained cell proliferation and/or
differentiation such as cancer, vascular diseases such as

hypoxic pulmonary hypertension and other hypertensive
pulmonary vascular diseases, systemic hypertensive dis
60

eases, intimal hyperplasia secondary to balloon angioplasty
(“re-stenosis”), intimal hyperplasia which may result in

prosthetic vascular graft failure, cerebral ischernic injury,

The present inventors have discovered two novel classes

of transport inhibiting substances which differ fundamen

hyperproliferative skin diseases such as psoriasis leukemia, V

tally from previous transport inhibitors. These inhibitory

gastric ulcer, hyperpoxic lung injury, and infectious diseases

substances comprise a modi?cation of a well-accepted

approach for constructing conjugates between endogenous

65

such as those caused by parasitic protozoa.
However, the invention has broad utility in treating any

chemicals that are normally actively transported into cells

disease condition wherein the onset or progression of the

and low-molecular weight drugs as a means for enhancing

disease condition requires the uptake of a speci?c substance

5,456,908
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by speci?c cells.

DETAILED DESCRIPTION OF THE
INVENTION

14C-polyarnines in cultured pulmonary artery smooth

The transport inhibitory substances of the present inven
tion may be synthesized by known methods and reagents for
conjugating desired substances. As discussed supra, the
conjugates between the targeted substance and the protein or
polymers of the targeted substance may be directly linked or
may be linked using known coupling agents. The selection

muscle cells. Conjugates were added to the cultures simul

of the speci?c coupling agent or reagent is largely a matter

taneously with 3 M of a speci?c 1‘lC-polyarnine and

of convenience and depends upon factors including the
available coupling agents and the speci?c targeted substance
being conjugated and functional groups which are available
for covalent attachment. Examples of suitable coupling
agents include, homo and heterobifunctional coupling
agents and reagents such as cyanogen bromide, diisocyan
ates, dialdehydes, glutaraldehydes, carbodiimides, in par

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. lA-lC: Etfect of polyarnine-polyarnine conju~

gates, putrescine~putrescine (top), spermidine-spermidine
(middle), and spermine-spermine (bottom) on uptake of free

allowed to incubate for 30 minutes after which the content
of cell-associated radioactivity was determined. Each point
is the mean i the standard error of at least 6 replicates. These

data indicate that the Put-Put and Spm-Spm conjugates
discriminate between the non-selective and selective sper~

15

midine/spermine transport systems and that the Spm-Spm
conjugate e?’ectively blocks the import of all three

ticular, N-(8-maleimidobutyryloxy)-succinimide, 6‘malein
imido-hexanoic

polyamines.

acid

N-succinimidyl

ester

(MHS),

N-succinimidyl 3-(2-pyridyl dithio)propionate (SPDP), and

FIGS. 2A—2C: E?ect of polyamine-BSA conjugates,

l-ethyl-3-(3dimethylaminopropyl)carbodiimide.

BSA-putrescine (top), spermidine-BSA (middle), and sper

Methods for conjugating proteins and other organic sub

mine-BSA (bottom) on uptake of free l4C-polyamines in
cultured pulmonary artery smooth muscle cells. Conjugates

stances and reagents for facilitating such attachment are well
known in the art and are not a subject of the present
invention.

were added to the cultures simultaneously with 3 M of a

speci?c 14C-polyarnine and allowed to incubate for 30

The polymeric transport inhibiting conjugates of the
minutes after which the content of cell-associated radioac 25
present
invention will comprise a suf?cient number of
tivity was determined. Each point is the mean i the standard
molecules of the particular transported substance such that
error of at least 6 replicates. These data indicate that the
the conjugate is of a su?icient molecular weight to inhibit
Put-BSA and Spm—BSA conjugates discriminate between
the non-selective and selective spermidine/spermine trans

port systems and that the Spm-Spm conjugate effectively

30

stance.

blocks the import of all three polyamines.
FIGS. 3A—3C: E?’ect of polyarnine-polyarnine conju

The molecular weight of the subject polymeric conjugates

gates, putrescine-putrescine (top), sperrnidinespermidine
(middle), and spermine-spermine (bottom) on uptake of free

1‘*C-polyamines in cultured pulmonary artery smooth

35

(which blocked transport of the particular polyarnine mono

for 24 hours) increased polyamine uptake approximately

mer and which were apparently not themselves internalized)

350% relative to control cells. Conjugates were added to the

M of a speci?c 14C-polyamine and allowed to incubate for

were synthesized using putrescine, sperrnine or spermidine
40

with polyarnine uptake stimulated by inhibition of de novo

15,000.
45

FIGS. 4A-4C: Effect of polyarnine-BSA conjugates,

putrescine-BSA (top), spermidine-BSA (middle), and sper
50

araldehyde.
55

which the content of cell-associated radioactivity was deter
mined. Each point is the mean i the standard error of at least

6 replicates. These data indicate that polyamine-BSA con
jugates inhibit both transport systems in cells with
polyarnine uptake stimulated by inhibition of de novo

The invention further embraces heteropolymeric conju
gates wherein the repeating monomeric units in the polymer
comprise several different transported substances, e.g., het
eropolymers wherein the monomeric units comprise differ

ent polyamines. Thereby, the resulting polymeric conjugate
should provide for the selective inhibition of cellular uptake
of each of the different polyamines contained in the poly
60

polyarnine synthesis.

meric conjugate.
The subject polymers of transported substances, e.g.,
polyamines, may further be conjugated to a moiety which
provides for the targeting of the conjugates to desired cells.

FIG. 5: Concentration-dependent cytotoxicity of Poly
PUT conjugate in a parental lineage of human uterine
sarcoma cells (MES-SA) and variants (DX5) expressing

wherein TS is a normally transported substance, and n
comprises the number of such moieties. However, as dis
cussed supra, the TS moieties, e.g., a polyarnine, may also

be indirectly attached using a coupling agent such as glut

cells. Conjugates were added to the cultures after DFMO

treatment and simultaneously with 3 M of a speci?c
14C-polyamine and allowed to incubate for 30 minutes after

In general, the subject polymeric conjugates will com
prise the generic homopolymen'c structure:
(T 5),.

polyarnine synthesis.
mine-BSA (bottom) on uptake of free 14C-polyarnines in
cultured pulmonary artery smooth muscle cells treated with
DFMO. DFMO treatment (1 mM for 24 hours) increased
polyarnine uptake approximately 350% relative to control

as the polyarnine monomer and glutaraldehyde as the cou

pling agent which comprised molecular weights in excess of

30 minutes after which the content of cell-associated radio
activity was determined. Each point is the mean i the
standard error of at least 6 replicates. These data indicate that

polyarnine conjugates inhibit both transport systems in cells

of transported substances may vary from about 3,000 to
about 500,000, more preferably from 15,000 to about 100,
000 and most preferably from about 15,000 to about 30,000.

For example, e?icacious polymeric polyarnine conjugates

muscle cells treated with DFMO. DEMO treatment (1 mM
cultures after DFMO treatment and simultaneously with 3

uptake of the targeted substance without itself being inter
nalized by cells which normally uptake the targeted sub

For example, the subject transported substance polymers
65

may be attached to cell surface antigens, receptors, glyco

drug resistance secondary to expression of the p-glycopro

proteins, and lectins which are expressed on cells involved

tein. Each point is the mean i SEM of 3 replicates.

in a particular disease condition such as cancer.

5,456,908
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The second novel class of novel inhibitors discovered by
the inventors comprises conjugates of a transported sub
stance and a protein. These conjugates will in general

As discussed supra, in the preferred embodiment the

transported substance contained in the subject transported
substance polymeric complexes or transported substance

comprise the generic formula:

protein or polypeptide conjugates will comprise one or more

polyamines or acetylatal derivatives thereof, and most pref

erably spermine, spermidine or putrescine.
However, the invention has broad applicability in provid
ing conjugates which selectively inhibit the cellular uptake
of any normally transported substance. Examples of trans

wherein TS is a normally cellularly transported substance,
e.g., involved in a particular disease condition and P com

prises a protein or polypeptide, e.g., a biologically accept
able protein or polypeptide. The transported substance and
the protein or polypeptide may be directly conjugated or
may be indirectly attached using coupling agents such as
were described supra. Methods for conjugating proteins or
polypeptides to desired compounds are well known to those
of skill in the art. The particular coupling method, reagents,
and coupling agent are again largely a matter of conve

10

porter pathways other than that for the polyamines contem
plated for use in the invention include amino acids, multiple
drug resistance transporters such as p-glycoprotein (p~gp),

lipoproteins such low density lipoprotein (LDL), neurotrans
mitters, scrotonia, sugars, homones, succharides, lipids,
organic anions and cations, purines and steroids.

The subject transported substance polymeric conjugates

nience. Also, the preferred coupling agent again comprises

and transported substance-protein or polypeptide conjugates

glutaraldehyde.

have useful in vivo and in vitro applications for selectively

The protein or polypeptide to which the transported
substance is attached will comprise any protein of suf?cient
molecular weight to provide a conjugate which selectively

blocking cellular transport of the particular transported
20

substance or substances.

In vitro usage will include the addition of the subject
conjugates to cell cultures which comprise a cell which

blocks cellular uptake of the particular transported substance
and which itself is not internalized. Also, the selected

normally uptakes the particular transported substance,

polypeptide should preferably not be toxic. In the preferred
embodiments such proteins will comprise proteins of known
application in protein conjugates for in vivo usage such as
globulins and albumin proteins, e.g., bovine serum albumin,
ovalburnin, key hole impact hemocyanin and human serum

thereby the effect of uptake of the particular substance on
25

polyamines this will be highly bene?cial since millions are
spent in laboratories around the world to conduct studies

relating to the cell biology of polyamines. However, prior to

albumin.

As stated supra, the molecular weight of the subject

the present invention there were no pharmacological agents
30

transported substance-drug conjugates should be suf?cient
to block transport of the particular transported substance and
be such that the conjugate is substantially non-internalized.
The molecular weight of such conjugates will typically
range from about 10,000 to about 500,000, preferably from
about 50,000 to about 250,000 and most preferably from
about 65,000 to 100,000.
In the preferred embodiment the transported substance

cells such as cancer cells and vascular cells, such as pul
35

pulmonary hypertension caused by hypoxia occurs by a
biological mechanism involving increased polyamine trans
port rather than increased de novo polyamine synthesis.

Thus, the subject conjugates should facilitate further study
of the mechanism of pulmonary hypertension and hypoxia.
40

In the case of cancer, it is believed that polyamine

transport is required for the proliferation of such cells. Also,
it is known that many cancer cells express a specialized

jugate which inhibits the cellular uptake of several normally

membrane pump called the “Multiple Drug Resistance"
(MDR) transporter. This is an important system for it

transported substances.
As with the polymeric or transported substance conju

which selectively inhibited the polyamine transport system.
Particular examples of cells wherein polyamine transport
is believed to be important include actively proliferating
monary vascular cells. For example, it is believed that

will comprise a polyamine, e.g. , putrescine, spermine or

sperrnidine. It is also within the scope of the present inven
tion to attach the protein or polypeptide to several different
transported substances, e.g., polyamines, to provide a con

cellular functions may be delineated. In the case of

45

enables cancer cells to develop resistance to anti-tumor

gates, the subject transported substance-protein or polypep

agents by effectively pumping the anti-tumor agent out of

tide conjugates may optionally be attached to a moiety
which provides for these conjugates to be selectively tar
geted to desired cells, e.g., cancer cells, or the polypeptide
or protein used for conjugation may itself provide for
targeting to speci?c cells.
Examples of suitable targeting moieties include cell sur

the cells. One MDR transporter has been characterized by
previous researchers to comprise a 12 domain protein which
spans the cell membrane. Among the numerous lZ-domain
membrane spanning proteins known, one is a putrescine
transporter found in bacteria. This, coupled with the fact that
both of these transport systems are actively expressed in

50

face antigens, receptor proteins and polypeptides, single

cancer cells lead the present inventors to believe that these

chain antibodies, glycoproteins, lectins, etc., which selec
tively bind to moieties expressed on speci?c cells wherein
the uptake of a normally transported substance is to be
inhibited. For example, a polyamine such as sperrnidine,
sperrnine or putrescine may be conjugated to a speci?c
cancer cell surface polypeptide or protein to provide conju

systems may be related. However, the present inventors do
55 not wish to be bound by any theory.
Data contained infra supports the inventors’ belief and
further indicates that polyamine transport results in poten
tiation of the activity of anti-rumor agents. Therefore, the

gates which are selectively targeted to cancer cells and

60

subject polyamine inhibitors possess utility in that they

which inhibit the uptake of the respective polyamine by such

two transport systems. Also, they possess utility in that they
assist in identifying in vitro anti-rumor compounds whose
activity may be potentiated by the addition of polyamine
transport inhibitors.

cells.

The selection of a particular targeting moiety will of
course depend upon the targeted cells. For example, if such

targeted cells comprise cancer cells, the targeting moiety

provide further in vitro evidence as to relatedness of these

65

The amount of the subject inhibitor conjugates which are

will preferably comprise a ligand which binds to a moiety

added to a particular cell culture will comprise an amount

expressed on the surface of such cancer cells.

which is at least su?icient to inhibit transport of the particu

5,456,908
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lar transported substance, e.g., a polyamine. In general, the
amount of the particular inhibitor conjugate added to the cell
culture will range from about 0.001 M to about 500 M,
preferably from about 0.1 to about 100 pM, and most
preferably from about 0.1 M to about 20 pM. However, this

pulmonary hypertension. Also, it should facilitate the design
of suitable pharmacological agents for treating this condi

amount will vary dependent upon the nature of the particular

pharmaceuticals, e.g., orally, intranasally, intratracheally, or
via injection routes, e.g., via intramuscular, intravenous,

conjugate, the substance for which cell uptake is being
inhibited, the particular cells being cultured and their capa
bility to transport this substance.
In the case of polyamine transport inhibitors, effective
dosages can readily be determined by adding incremental

tion.

The subject transport inhibitor conjugates will be admin
istered to animals by known methods for administering
intraperiotenal or subcateneous routes. Preferably, the sub
10

amounts of the particular conjugate to cell cultures and

assessing the effect on polyamine uptake using well known
assays described, e.g., in Kameji et al, Amer. J. PhysioL, 256
(Cell Physiol 25), Cl 60—Cl67, 1989; Morgan et al, Biochem
J., 256, 413-417, 1992; Rannels et al, Am. J. Physiol, 287,
L346-L353 1989; Kamagai et al, Amer. J. Physiol, 256,
G905-G910, 1989; Nicolet et al, Biochem. J., 269, 629-632,
1990.
The subject transport inhibitor conjugates also comprise

ject conjugates will be administered by injection, e.g.,
intraperitoneally, intravenously, intramuscularly, with the
intravenous route being most preferred. The subject conju
gates may be rendered into pharrnaceutically acceptable
form by the addition of known pharrnaceutically acceptable
carriers and excipients.
The subject polyamine transport inhibitor conjugates may
also be administered in combination with DFMO. This will

enable simultaneous inhibition of polyamine transport and
synthesis and a determination of the in vivo effects thereof,
e.g., in a particular disease condition, such as cancer or

hypoxic pulmonary hypertension.

in vivo use both from a research and therapeutic standpoint.

The most important in vivo application of the subject

For example, the subject conjugates may be administered to
animals, e.g., mice, rats, monkeys, and the like to study the

transport inhibitor conjugates will comprise their use as
therapeutic agents. According to the present invention, con

effect of inhibited transport of the particular substance on a

particular disease condition. In particular, the subject

25

polyamine transport inhibitors may be administered to ani

mals having a condition involving polyamine transport, e.g.,

treatment of any disease condition wherein the cellular
transport of a speci?c substance is required or is substan
tially involved in the disease condition.

cancer, vascular disorders such as pulmonary hypertension

and other hypertensive pulmonary vascular disorders, infec
tious disorders, hyperproliferative skin diseases, cerebral

30

ischemic disorders, etc. Thereby, the in vivo role of
polyamine transport on the particular disease condition may
accurately be assessed.

An important application of the subject conjugates will
involve administration of the subject conjugates to animals

jugates may be synthesized which selectively inhibit the
cellular uptake of any normally transported substance.
Therefore, the subject conjugates may be used for the

35

having implanted tumors or cancer cells, e.g., rats, as

Examples of other transported substances involved in
disease conditions include amino acids, multiple drug resis
tance transporters such as p-glycoprotein (p-gp), transported
polyproteins such as low density lipoprotein (LDL), neu—
rotransmitters, serotonin, sugars, hormones saccharides, lip
ids, organic anions and cations, purines and steroids.
Moreover, given their size, selectivity and mode of action
(at the cell membrane level) the subject conjugates should

studying the eifect of the conjugates on tumor growth and

metastasis. Also, the subject conjugates may be administered

not produce any adverse effects since they are not intemal
ized by cells and further do not appear to block cellular

in conjunction with one or more anti-tumor agents to ani

mals having implanted tumors. Thereby, the effect on e?‘i
cacy of the particular anti-tumor agent by the particular
conjugate may be assessed. As discussed supra, given the
similarities of the MDR pump and the polyamine transport
system, and the data obtained by the present inventors, it is

40

expected that the subject polyamine conjugates will poten
tiate the el?cacy of many anti-tumor agents by reducing the

45

transport of non-targeted substances.
In the case of the exempli?ed polyamine transport inhibi

tor conjugates, these conjugates will be used therapeutically
in the treatment of disease conditions wherein polyamine
transport plays a substantial role in the disease condition.
Disease conditions wherein increased polyamine transport is
believed to exert a signi?cant effect include diseases involv

e?iciency of the MDR pump. Also, such in vivo studies will

ing abnormal cell growth, differentiation and proliferation.

provide further evidence regarding the biological link

Examples of such disease conditions include cancer,

between these two transport systems.
The amount of the particular conjugate which is admin

hypoxic pulmonary hypertension and related hypertensive
pulmonary vascular diseases, intimal hyperplasia, secondary
to balloon angioplasty (“restenosis”), intirmal hyperplasla

istered to an animal will depend upon factors such as the

particular animal, the speci?c disease condition, the particu

which may result in prostnetic vascular graft failure, cerebral
ischernic injury, hyperproliferative skin diseases such as

lar nature of the conjugate, and the speci?c transported
substance for which uptake is to be inhibited. In general, the
amount administered will provide for levels of polyamines
in the blood ranging from about 0.001 to 5000 M, prefer
ably about 0.01 to 2000 M in the blood, and most prefer

psoriasis hypertensive diseases, gastric ulcers, leukemia
systemic hypertension diseases, hyperoxic lung injury, and
infectious diseases such as parasitic protozoan diseases.
The subject transport inhibitor conjugates when used as
therapeutic agents may be administered via any known

ably will provide for polyamines blood levels ranging from
about 0.1 M to 200 M.
Another important in vivo usage of the subject polyamine
transport inhibitor conjugates will comprise administration
to animals, e.g., rats, to evaluate the effect of these conju

60

intravenously, intramuscularly, subcutaneously, or intraperi

toneally.

gates on the induction of ?bronectin synthesis and other

cellular events by hypoxia in pulmonary artery smooth
muscle cells and the effect on pulmonary arterial blood
pressure. Such animal studies will provide in vivo evidence

that increased polyamine transport is involved in hypoxic

pharmaceutical mode of administration, e.g., orally, intra
venously (via injection), intratracheally, or rectally. Prefer
ably, the conjugates will be administered via injection, e.g.,

65

The effective dosage of the subject conjugate will com
prise dosages which are at least su?icient to inhibit transport
of the particular targeted substance and which do not cause
any adverse effects. Such dosages will vary dependent upon

5,456,908
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factors including the speci?c disease condition being
treated, the particular conjugate being administered, its

The two types of polyamine inhibitors tested in this

example and the following examples comprise: (i) conju

biological half-life, its ability to be delivered to the targeted
site, etc. As discussed supra, the subject conjugates may
further comprise a targeting moiety which enhances their
selective delivery to targeted cells, e.g., tumor cells.
An e?‘ective therapeutic range will typically be su?icient
to provide for polyamine concentrations ranging from 0.001
to 5000 M, preferably ranging from about 0.01 M to 2000
M and most preferably ranging from about 0.01M to about

gates between bovine serum albumin (BSA) and either

putrescine, spermidine or sperrnine using glutaraldehyde as
a coupling agent; and (ii) large polyamine-polyamine poly

meric conjugates of putrescine (Put-Put), spermidine (Spd
Spd) and spermine (Spm-Spm) using glutaraldehyde as a
coupling agent. The molecular weight of the synthesized

polyamine-BSA conjugates exceeded 65,000 daltons,
whereas the polyaminepolyamine conjugates comprised a

200 M.
The subject transport inhibitor conjugatesmay be admin

molecular weight in excess of 15,000 daltons.
Mass spectrum data has demonstrated that the most

istered singularly or in combination with other drugs suit

able in treating the particular disease condition. Also, the
subject transport inhibitor conjugates may be administered
together with substances which block synthesis of the par~

15

ticular transported substance so as to inhibit both the trans

port and synthesis of a transported compound involved in
the particular disease condition. For example, the subject
polyamine transport inhibitor conjugates may be adminis'

20

repeating SPM-glut-SPM units off a longer polymeric SPM

25

free to interact with the transporter binding sites. Also, these
conjugates were found to retain biological stability for at
least a month after synthesis.

tered in combination with DFMO, which is used to treat
disorders wherein the cellular concentration of polyamines
is involved in the particular disorder.

As discussed supra, an important therapeutic application
of the subject polyamine transport inhibitor conjugates will

effective conjugate, polymeric spermine exhibited a molecu
lar weight of about 25.5x0.5 KDa. Results of protron
magnetic resonance, nuclear magnetic resonance, and mass
spectral analyses indicate that the molecule exhibits a
branched structure having relatively short extensions of
glut-SPM backbone. The SPM moieties at the termination of
each branch and backbone appear to be unconstrained and

involve the treatment of cancer since polyamine transport

Each of these polyamine-polyamine polymeric conjugates

and synthesis is implicated in abnormal cell differentiation,
growth and cell proliferation.

and the polyamine-BSA conjugates were added to pulmo
nary artery smooth muscle cell cultures at concentrations

In the treatment of cancer, the subject polyamine inhibi

ranging from 0-20 uM, along with 3 M of a speci?c

tors may further be administered in combination with known 30 14C-polyamine and allowed to incubate for 30 minutes.

anti-neoplastic agents since data disclosed herein indicates
that inhibition of polyamine transport may potentiate the
e?icacy of some anti-neoplastic agents, most likely because
of inhibition of the MDR transporter system. Therefore, the
use of the subject polyamine inhibitors in combination with

After this 30 nrinute period the cell-associated radioactivity
was then measured to determine the uptake of polyamine by

anti-tumor activity.
Another important therapeutic application of the subject
polyamine inhibitors comprises the inhibition of hypoxic

polyamine-polyamine conjugates on polyamine uptake,
whereas FIGS. 2A—2C depicts the effect of the polyamine
BSA conjugates on polyamine uptake.

pulmonary hypertension since data disclosed infra indicates
that the subject conjugates inhibit ?bronectin synthesis by
pulmonary artery smooth muscle cells, the synthesis of
which is believed to be implicated in pulmonary hyperten

Put-BSA inhibited uptake of putrescine in the pulmonary

the cell culture.
The results of these experiments are shown in FIGS.
35
1A-1C and 2A-2C. FIG. 1A—C depicts the effects of the
one or more anti-neoplastic agents should result in enhanced

It can be seen from FIG. 1A and 2A that both Put-Put and

510m.

The following examples are offered to illustrate the
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present invention and should not be construed in any way as

spermidine to a greater extent than spermine.
Also, the results contained in FIG. 1C and 2C indicate that

limiting its scope.
EXAMPLE ONE
50

Effect of Polyamine-Polyamine Conjugates and

Polyamine-BSA Conjugates on Polyamine Uptake
in Pulmonary Artery Smooth Muscle Cells
It has been previously shown that cultured pulmonary
artery smooth muscle cells, like may other cell types,
express two ditferent transport systems for polyamines; a
“nonseleetive” carrier for putrescine, spermidine and sper
mine, and another carrier that is “selective” for spermidine
and spermine. Based on this information, experiments were
designed to determine whether the addition of the subject

artery cell cultures but failed to impair the uptake of sper
midine and spermine.
By contrast, FIG. 1B and 2B demonstrate that both
Spd-Spd and Spd-BSA inhibited uptake of putrescine and

55
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polyamine inhibitors, in concentrations ranging from O-ZO
pM could block polyamine uptake by cultured pulmonary

both forms of the sperrnine inhibitor, Spm-Spm and Spm
BSA, inhibited uptake of putrescine, spermidine and sper
mine.
Control experiments were also conducted wherein the
same concentrations of BSA were added to pulmonary artery
smooth muscle cell cultures together with 3 M of a speci?c
14C-polyarnine and the cultures allowed to incubate for 30
minutes. Cell associated radioactivity was then measured.

These results (not shown) indicated that free BSA (not
conjugated to BSA) did not inhibit the uptake of putrescine,
spermidine or spermine. Thus, the di?°erential, concentra
tion-dependent e?°ects of the respective transport inhibitors
on the uptake of the respective polyamines indicate that they

prevent the uptake of polyamines by cultured pulmonary

could discriminate between the “nonselective” and “selec

artery smooth muscle cell cultures and also that these
inhibitors apparently interact selectively with the two
polyamine transporters believed to exist in pulmonary artery

tive” polyamine transporter.

smooth muscle cells as well as other cell types.

smooth muscle cells. Also, it was a further object of the

experiment to determine whether the particular inhibitor

65
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EXAMPLE 2

particular pathologically-relevant cells, the following
experiments were conducted.

Effect of the Subject Polyarnine Inhibitors of

Speci?cally, the eifect of the subject spermine-spermine

DFMO Stimulated Polyamine Uptake

conjugates on two types of cultured bladder cancer cells was

The present inventors have previously shown that the
inhibition of polyamine synthesis in pulmonary artery

examined, the ?rst designated DXE, are resistant to anti
tumor drugs and the second designated MESSE are sensitive

smooth muscle cells with DFMO causes a compensatory
increase in the activity of both the selective and non

to such anti-tumor agents. Spermine-sperrnine conjugates
were selected since the available data indicates that this

selective polyamine transporters. Speci?cally, putrescine,

conjugate is an eifective and potent polyamine transport
inhibitor for both polyamine transport systems. As shown in
Table 1 set forth below, it was found that 20 M of the

spermidine and sperrnine uptake increases about 3-5 fold in
comparison to cells not treated with the polyamine synthesis
inhibitor. This phenomenon has been noted for numerous

other cell types and probably explains why the therapeutic

spermine-spermine conjugate reduced uptake of sperrnidine

e?icacy of DFMO is limited. Along with the induction of
polyamine transport with DFMO, we have also found that
culture of pulmonary artery smooth muscle cells in a
hypoxic environment increases transport, however, not to

in both cell populations. Thus, the results indicate that the
15

subject conjugates should have both clinical and therapeutic
for applicability in inhibiting polyamine transport by cancer
cells. Also, the subject conjugates should provide utility in

the same extent as DFMO. This is important since hypoxia

vivo and in vitro for studying the relatedness of the

is a pathologically relevant stimulus for pulmonary hyper

polyamine transport system and the multi-drug resistance
transport system.

tension.
Accordingly, similar experiments were conducted to

20

TABLE 1

determine if the induction of polyamine transport by DFMO

and hypoxia would be prevented by the polyamine inhibitors

Impact of Spm-Spm Conjugate on Spermidine Uptake by Drug

of the present invention. The results of these experiments are
shown in FIGS. 3A—3C and FIGS. 4A-4C. Speci?cally,

putrescine-putrescine, spermidine-spermidine, spermine

sensitive (MESSE) and Drug-resistant (DXE)
Human Bladder Cancer Cells in Culture.
25

spermine, putrescine-BSA, sperrnidine-BSA and spermine
BSA inhibitor conjugates were added in concentrations

ranging from 0 to 20 M to pulmonary artery smooth muscle
cell cultures which had been treated with DFMO. DFMO
treatment consisted of the addition of 1 mM of DFMO to the
cultures followed by a 24 hour incubation period. The

Spermidine Uptake (uM/30 min/pg protein)
Cell Type

Control

+20 M Sprn-Spm

MESSE
DXE

5.53 i 0.35
1.00 i- 0.03

0.33 i 0.14
0.32 i 0.02

30

polyamine uptake was increased relative to control cells by

EXAMPLE 4

about 350%.

After DFMO treatment and incubation, the respective
conjugates were added in amounts ranging from about 0 to

Effect of the Subject Conjugates on Uptake of
35

Amino Acids

20 M simultaneously with 3 M of a speci?c 14C
As discussed supra, there are some parallels between the

polyarnine and the cells allowed to incubate for 30 minutes.
After incubation, the content of cell associated radioactivity
was determined. The results in both FIGS. 3A—3C and FIG.

4A-4C indicate that the subject polyamine conjugates

40

inhibit both transport systems in cells wherein polyamine
uptake has been stimulated by inhibition of de novo

acids as well as polyamines.
To prove that this was not occurring, the effect of the

polyamine synthesis.

subject polyamine-BSA and polyamine-polyamine conju

Similar experiments were conducted to determine the

effects of the subject inhibitor conjugates on hypoxic pul

transport of polyamines and amino acids. Accordingly, the
present inventors considered the possibility that the subject
polyamine transport inhibitors may not be selective, i.e.,
they may inhibit the uptake of naturally occurring amino

45

gates on the uptake of the non-metabolizable amino acids,

speci?cally methyl amino isobutyric acid and lysine was
examined in cultured pulmonary artery smooth muscle cells.
These amino acids were selected because lysine is positively
charged like the subject polyamines and also because both

monary artery smooth muscle cells. These results are not
shown, however, the results were identical to those obtained

in the DFMO-treated cells. The observed results indicated

that both types of inhibitors suppressed polyamine uptake in

an identical manner to their actions in control cells in the 50 these amino acids use diiferent transport systems which are

distinct from the polyamine transport system.

absence of DFMO or hypoxia.

The results of this experiment are found in Tables 2A and
2B set forth on the following page:

The putrescine conjugates inhibited accumulation of
putrescine to a greater extent than sperrnine and sperrnidine
in DFMO cells (as shown in FIG. 3A and 4A), while the

TABLE 2A

sperrnidine and sperrnine conjugates inhibited uptake of all
polyamines (as shown in FIGS. 3B, 3C, 4B and 4C). Thus,

Impact of Polyarnine-Polyamine Conjugates (20 M) on Uptake of
Non-Polyarnine Amino Acids in Cultured Pulmonary

the inhibitors are effective and retain their selectivity even

Artery Smooth Muscle Cells

under conditions of augmented polyamine transport.
EXAMPLE 3

PERCENT CONTROL UPTAKE
60

Amino Acid

The Effect of the Subject Polyamine Conjugates on
Cultured Bladder Cancer Cells
The previous examples related to the effects of the subject
conjugates on pulmonary artery smooth muscle cells. To
prove that these phenomena were not cell speci?c and that
the invention has broad applicability for other cell types, in

Put—Put

Spd-Spd

Spm-Sprn

MAIBA*

65

25PM

106:4

ll4i5

1261*5

501M

103 i 6

106 i 5

H7 1'" l2

Lysine

5,456,908
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polyamine-polyarnine conjugates at 4° and 37° C., the

TABLE 2A-continued

cell-associated radioactivity was then determined. In accord
with the inventors’ expectations, there were no discernable
di?erences in the content of cell-associated radioactivity
between cells at low and normal temperature (data not

Impact of Polyamine-Polyamine Conjugates (20 M) on Uptake of
N on-Polyamine Amino Acids in Cultured Pulmonary
Artery Smooth Muscle Cells
PERCENT CONTROL UPTAKE

shown).
Amino Acid

Put-Put

Spd—Spd

Spm-Spm

2.5 M

105 i 4

103 i 13

99 i 11

Also, a second experiment was conducted to determine

whether the inhibitors internalize cells using confocal
microscopy, using methods such as an described in Fisher et

*MAIBA: methylaminoisobutyric acid

al, Nucl. Acids Res., 21, 3857-3865, 1993; Petroll et al, J.
Microsc. 170, 213-219, 1993; and Schipper et al, Exp. Cell
Res., 207, 62—67, 1993. The BSA portion of a spermine-BSA

TABLE 2B

conjugate was labelled with the ?uorescent molecule
rhodamine and confocal. Microscopy was then used to

Impact of Polyamine-BSA Conjugates (20 M) on Uptake of
Non-Polyamine Amino Acids in Cultured Pulmonary
Artery Smooth Muscle Cells

determine the cellular localization of the conjugate.

PERCENT CONTROL UPTAKE

Amino Acid

Put-Put

Spd-Spd

MA1BA*

2.5uM
5.0 M

This technique examines the cells much like a CAT scan

Spm-Spm
20

121 i2
126 i 10

1151-6
120 i 7

l98i8
129 i ll

ll3il8

lOOiS

109i8

of a cell, the uppermost of which comprises the cell mem

brane, whereas a mid-level picture would likely capture the
cell nucleus, etc. Using this technique, it was found (results

Lysine
2.5uM

25

not shown) that all of the cell ?uorescence was localized to
the cell membrane and that no ?uorescence would be

detected in any interior portion of the cell.
Based on both the temperature-dependent experiments
and the ?uorescence studies using confocal microscopy, it is

*MAIBA: methylaminoisobutyric acid

These results demonstrate that neither the polyarnine

polyamine conjugates or the polyarnine-BSA conjugates
impaired the uptake of these two amino acids. Thus, this
provides further evidence that the subject polyarnine trans
port inhibitors are selective for inhibiting polyarnine trans
port. This is further supported by the fact that even within
the different polyarnine conjugates there are variable e?°ects
on uptake of the di?erent polyarnines, e.g., Put-Put and
Put-BSA inhibited the uptake of putrescine but not spermine

examines the human body. Essentially, the microscope takes
pictures of discrete sections through the vertical dimension

30

believed by the present inventors that the subject polyamine
transport inhibitors act at the level of the cell membrane and
do not access the cell interior.

35

EXAMPLE 6

or sperrnidine.

Biological Eifects of the Subject Polyarnine

EXAMPLE 5
40

Determination as to Whether the Subject Polyamine
Conjugates are Intemalized by Treated Cells

The inventors considered the possibility that the subject
inhibitors do not block polyarnine transport, but rather

In order to determine the biological effects of the subject
inhibitors on cells, several experiments were conducted. For
example, it was observed that treatment of pulmonary artery

smooth muscle cells with 30 M of the subject conjugates
45

merely substitute for the naturally-occurring polyarnines and
are thereby transported into the cell where they may exert
some biological activity. However, this was considered
SO

polyamine transporter is temperature sensitive. At low tem
perature the transporter is inoperative and polyarnines asso

artery smooth muscle cells with the radioactive labelled

e?’ected because hypoxic pulmonary hypertension is accom

panied by the deposition of large quantities of ?bronectin
around pulmonary arteries. Therefore, there is some belief

by researchers, including the present inventors, that the
increased deposition of this protein may be an important

ciated with the cell are bound non-speci?cally to the mem

conditions. Therefore, radioactive polyarnine-polyamine
conjugates were synthesized using radioactive polyamines
(analogous to the method for assessing polyamine uptake in
the previous examples). After incubation of pulmonary

?bronectin synthesis by hypoxic in pulmonary artery
smooth muscle cells was determined. This experiment was

Two strategies were devised to determine whether the
conjugates internalized into the cell or remained con?ned to
the cell surface. In the ?rst experiment, the inventors made
use of their previous observation that the operation of the 55

brane. Thus, it was reasoned that if the subject inhibitors
access the cell interior via the polyamine transporter, then
there should be substantial di?erences between the cell
content of the inhibitors at normal and low—temperaturev

did not result in exclusion of the vital stain tryptan blue. This

provides further evidence that the conjugates are not overtly
toxic.
Also, the effects of Spm-Spm on the induction of

highly improbable given that the molecular weight of the
subject conjugates which for both classes of inhibitors is
respectively in excess of 15,000 and 65,000 daltons.

Inhibitors

60

cause of the sustained elevation in pulmonary arterial blood
pressure. Also, hypoxia seems to cause pulmonary hyper
tension by a mechanism related to increased polyarnine
transport rather than increased de novo polyarnine synthesis.

The availability of the subject polyarnine transport inhibi
tors therefore provided an opportunity to test the hypothesis
that hypoxia evokes synthesis and release of a pathologi
65

cally-relevant protein by a polyarnine transport-dependent
mechanism.
The results of this experiment are contained in Table 3.

5,456,908
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TABLE 3

TABLE 4A

Impact of DFMO and Spm-Spm Conjugate on Hypoxia-induced
Fibronectin Synthesis in Cultured Pulmonary

Impact of Spm-Spm Conjugate on Vinblasn'ne Uptake by Drug
sensitive (MESSE) and Drug-resistant (DXE)

Artery Smooth Muscle Cells

5

Human Bladder Cancer Cells in Culture

Fibroneetin Synthesis (OD/mg protein)
Exptl.

Group

vinblastine Uptake (dprn/30 min/pg protein)
DFMO +

Control

DFMO

Spm-Sprn

Sprn

Normoxic

0.08

0.07

0.05

0.04

Hypoxic

0.12

0.09

0.06

0.05

10

Cell Type

Control

+20 M Spm-Spm

MESSE
DXE

9.7 i 0.3
10 i 0.2

13 i 0.3
14 i 0.1

In the control (non-hypoxic cells), inhibitors of de novo
1

'

nth

i

'

FMO f '1

reduce

TABLE 4B

eu

po yalimne Sy es s ‘.mt.h D
al ed to.
the ac
mulation of ?bronectrn 1n the culture medium. By contrast, 15

inhibition of polyamine transport with the Spm-Spm con
jugate resulted in a substantial reduction of accumulation of
?bronectin which was not suppressed by the addition of
DFMO. This is consistent with the inventors’ belief that de
novo synthesis of polyarnines is not involved in the response

vinblastine Uptake (dprn/30 min/pg protein)

20

Control

1 20 PM Spm-Spm

MESSE
DXE

6.2 i 0.6
3.2 i 0.7

8.3 i 0.7
8.3 i 1.3

These results are extremely exciting since they provide
25

polyamine transport pathways. Also, they expand the poten
tial utility of the subject polyamine transport inhibitors as
anti-neoplastic agents. In particular, administration of the

human bladder cancer cells was examined. It is known that
cancer cells express a specialized membrane pump called

subject inhibitors to cancer subjects should prevent cancer

cells by inhibiting uptake of polyarnines required for abnor
30

mal cell proliferation.
Also, when the subject inhibitors are administered in

enables tumor cells to become resistant to anti-tumor drugs

conjunction with anti—cancer agents they should enhance
their efficiency by preventing their MDR-driven export from

by pumping an anti-tumor drug out of the cell interior.

One MDR transporter has been identi?ed by previous

tumor cells.

researchers which comprises 12 discrete domains that span 35
the cell membrane. Only about a half dozen of such 12-do
main membrane spanning type proteins are known in the art,
with one being the putrescine transporter isolated from

bacteria. Accordingly, the present inventors postulated that
the MDR pump and the polyamine transport system may be
functionally related, particularly given the fact that both
transport systems are highly expressed in tumor cells.

Cell Type

further evidence regarding the link between the MDR and

hypoxic pulmonary hypertension.

the “Multiple Drug Resistance” (MDR) transporter. This
comprises a therapeutically signi?cant system since it

sensitive (MESSE) and Drug-resistant (DXE)
Human Bladder Cells Cultured in an Hypoxic Environment

to hypoxia. Moreover, the results indicate that the Spm-Spm
conjugate prevent a biological response (increased ?bronec
tin accumulation) believed to be strongly involved in

Also, the e?’ects of the subject polyamine inhibitors using
the transport of an anti-tumor drug (viablastine) by cultured

Impact of Spm—Spm Conjugate on Vinblastine Uptake by Drug

40

EXAMPLE 7

Effect of Polyarnine~conjugates on Cultured
Cultured Human Uterine Sarcoma and Leukemia

cells1
Cytotoxicity was assessed using the MTT assay in MES

To test this hypothesis, experiments were conducted to
determine whether or not inhibitors of the MDR transporter

SA and DX5 uterine sarcoma cell lines after a 24 hours

was assessed. The results obtained indicate that both agents

exposure to ascending concentrations of the putrescine poly
meric conjugates (poly~PUT conjugates) or its vehicle. As
shown in FIG. 5, the poly-PUT conjugate evoked concen
tration-dependent lethality in MES-SA and DX5 cells. Con
centrations of poly-PUT associated with 50% cytotoxicity
(IC50) were 60:12 and 200i20 M in MES—SA and DX5
cells, respectively. The cytotoxic effects of a polymeric
conjugate of sperrnine (poly-8PM), which suppresses trans
port of all three polyarnines in smooth muscle cells, in both

suppress polyamine transport by about 50-75% (data not

MES-SA and DX5 cells as well as K567 Human leukemia

would decrease polyamine uptake and, conversely, if inhi—
bition of polyamine import with the subject polyamine
conjugates would attenuate the MDR pathway, thereby

45

increasing the cellular content of anti-tumor drugs.
In the ?rst study, the effects of two‘agents known to inhibit

the MDR, i.e., veraparnil and cyclosporin, on polyamine
transport by cultured pulmonary artery smooth muscle cells

50

shown).
In the second study, culture of the above-noted MESSE

cells and their MDR-positive variants R7 cells are shown in
55

and DXE human bladder cancer cells were treated with

is cytotoxic in both cancer cells lines, with the MDR
positive variants being slightly more resistant. There are at

Spm-Spm and the tumor cell content of the anti-cancer drug
vinblastine was then measured.

As shown in Table 4A set forth below, Spm~Spm provided
modest, but signi?cant increases in the tumor cell content of

least several interesting aspects regarding these observa
tions. First, they demonstrate that the polyamine-conjugates
60

vinblastine. The data contained in Table 4B, set forth on the

following page, on the further suggest that the effect of
Spm-Spm on the retention of vinblastine by tumor cells is
dramatically more pronounced when the cells are rendered
hypoxic (a condition which may mimic that of cells com
prised in the center of a solid tumor). This may be explained
by the presence of another type of MDR transport system.

Table 5. Similar to the impact of poly-PUT, poly-SPM also

exhibit antineoplastic activity in two human cancer cells
lines. Second, the ?nding that the SPD-conjugate is some
what more potent than the PUT conjugate is consistent with
previous data indicating that the former is more effective in

blocking polyamine uptake in bovine pulmonary artery
65

smooth muscle cells (PASMCs). Further studies with the
SPM-conjugate are planned since this compound appears to
be the most potent polyamine transport inhibitor in pulmo

5,456,908
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nary artery smooth muscle cells (PASMCs) by virtue of its
TABLE 6

activity against both of the putative uptake pathways.
Finally, the nearly 3-fold difference in sensitivity between

Impact of poly-PUT and poly-SPM Conjugates on “C-SPD

DX5 and MES-SA cells suggests that the presence of the
MDR transporter could be’ a determinant of polyamine
transport activity and the attendant sensitivity of cancer cells

Uptake by MDR-negative (MES-SA) and MDR-positive (DXS)
Human Uterine Sarcoma Cells in Culture

% Speci?c Spermidine Uptake

to killing by polyamine transport inhibitors. This will be
addressed in further research.
The Conjugate Concentrations for experiments 7—l3 were determined based
on the molecular weight of free polyarnines and not the molecular weight of
the conjugates. For example, Poly-SPM concentrations would be 71 times
lower if they were determined based on molecular weight of Poly-SPM (25
KDa) rather than SPM which is around 350.

TABLE 5

MES-SA
K567
R7

IC50 (pM)
37
170
43
137

i
i
i
i

10
4.0
5
20

15

Resistance
4.5-fold
20

25

EXAMPLE 8

and Reduce Cell Polyamine Contents in Human

+20 M poly-PUT

MES-SA
DXS

100
100

84 i 2.4
57 i 3.3

+20 1.1M poly-SPM
15.6 i 0.6
6.2 i 0.13

E?ect of Polyamine Conjugates or Polyamine
Transport By Human Leukemia Cells
K567 leukemia cells and their MDR positive variant were
suspended at a density of 25x104 cells/n11 in serum free
medium. 1 M of 1‘*C-SPD was added and the cells were
incubated at 37° C. for 30 minutes. Incubation was termi

nated by rapidly chilling the cells on ice followed by

32-fold

Polyamine Conjugates Inhibit Polyamine Uptake

Control

EXAMPLE 9

Poly-SPM conjugate Cytotoxicity in Parental and MDR cells
Cell Line

Cell Line

centrifugation of 6000 RPM for 5 minutes at 4° C. The cells
were washed in ice-cold Tris buffer and centrifugated. The
pellet was lysed for 1 hour in 1N NaOH, and cell accumu

lated radioactivity was detemrined. 1‘iC-SPD uptake rate
was normalized to protein content. Both the K567 human

30

leukemia cell line and its MDR positive variant R7
expressed the polyamine transport system as shown in Table
7. Presence of 20 pM poly-SPM almost completely blocked
polyamine transport in K567 cells and its MDR variant R7.

Cancer Cells

TABLE 7
Additional studies were conducted to determine whether

MES-SA and DX5 cell 'lines express a polyamine transport
system, and, if so, whether this system(s) was inhibited by
the poly-PUT and poly-SPM conjugate. We focused our
e?orts on comparisons between the PUT and SPM conju

gates because these compounds appeared to discriminate
between the selective and nonselective pathways in bovine
pulmonary artery smooth muscle cells. In the current stud
ies, 14C-SPD was added in concentrations of 3 M and cells
were incubated for 30 minutes at selected temperatures (4°
and 37° C). The cells were rinsed with Hanks buffer,
digested for 1 hour in 1N NaOH, and cell-associated radio
activity was deterrnined. 1“C-SPD uptake rate was normal

Impact of poly-SPM Conjugates on 1‘*C-SPD Uptake
35

Human Leukemia Cell Lines

Speci?c Spermidine Uptake
Pmole/min/mg protein
40

45

polyamine accumulation. Addition of 20 pM SPM-SPM
conjugate reduced polyamine transport in MES-SA and DX5
cells by 10 and 3 fold, respectively. These results indicate
that the polyamine conjugates are effective in blocking

polyamine uptake blockade by promoting compensatory

synthesis.

Control

+20 |.tM poly-SPM

K567
K567/R7

77.3 i 1.5
27.0 i 0.5

0.7 i 0.03
0.73 i 0.09

EXAMPLE 10

To determine if the cytotoxicity and inhibition of

was,associated with depletion of cell polyamine contents,
50

additional experiments were conducted which used HPLC to
measure contents of PUT, SPD, and SPM in human uterine
sarcoma and leukemia cells in the presence of poly-SPM,

DFMO, and combined treatment with poly-SPM and
DFMO. The latter combination was tested to determine if
55

blockade of both transport and synthesis would promote
greater decreases in polyarrtine content than either interven
tion alone. As shown in Table 8, poly-SPM was eifective in

decreasing contents‘ of all polyarnines in all cells, while

polyamine transport in uterine sarcoma cells, which is
consistent with our previous experience in bovine PASMCs.
It also is noteworthy that the uptake of SPD, as assessed at
a single concentration (3 M), is substantially less in the
DX5 cell line(li0.03) than in control (5.5i0.35). The rea
sons for this are unclear, but it is hypothesized that the
presence of the MDR confers greater resistance to

increases in the activity of de novo pathways of polyamine

Cell Line

polyamine transport evoked by the polyamine conjugates

ized to protein content. Speci?c, carrier-mediated polyamine
uptake was calculated subtracting the total polyamine
uptake, detemiined at 37° C., from the non-speci?c
polyamine burden determined at 40° C. As shown in Table
6 MES-SA and DXS express a polyantine transport system
as evidenced by substantial temperature-dependent

by MDR-negative (K567) and MDR-positive (R7)

DFMO caused modest depletion of SPD but not SPM. This
is a signi?cant enlightening observation; numerous reports
have commented that DFMO fails to reduce SPM levels, and
this has been invoked as an additional explanation of the

relatively unimpressive cytotoxicity of DFMO. Indeed,
DFMO at 1 mM concentration was not toxic to either

MES-SA or K562 cells or their MDR-positive variants. By
65

contrast, poly-SPM, which decreases SPM contents along
with the other polyamines is highly toxic to all cells. It was
also observed that the e?’ect of poly-SPM+DFMO in com

5,456,908
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bination on cell polyarnine contents tended to be greater than

Making use of the fact that vinblastine is a well known
substrate for the MDR transporter, we reasoned that if

either agent alone, thus highlighting the interactive roles of

transport and synthesis in governing polyamine contents.

polyamine uptake blockade suppressed MDR activity, then

Further studies are planned to obtain further information

this should be re?ected as a decrease in the resistance of

regardiilg. mteracnons betwfien thase paihways ‘(ind thfm 5 MDR-positive cells to vinblastine-induced killing in concert
surtabrlrties as pharmacologic targets. It rs potentially sig-

.

.

.

.

.

.

.

.

with an increase in the cellular retention of the alkaloid. The

m?cant that the impact of poly-SPM on polyamrne contents

MTT

in the MDR-positive cells was somewhat less impressive

d t

aésfiy ‘was use

ff th Ic

0 qua“ 1 y

f

. b1 t.

e _ 50 or vm as me

than in the parental lines_ This ?nding may haw implica_
cytotoxrcrty in MES-SA and DX5 cells in the presence and
tions for mechanisms by which polyamine transport and 10 absence of treatment Wlth 100 PM Poly-PUT The calcula
MDR activity are interactive processes,
tion of cytotoxicity in these experiments accounted for the
lethality associated with use of the conjugate alone. As
shown in Table 9, DX5 cells were resistant to vinblastine
cytotoxicity relative to the parental MES-SA cells and
15 retained less vinblastine. The PUT-conjugate had little effect
on the lC5O for vinblastine cytotoxicity in MES-SA, but

TABLE 8
Cellular Polyamine content (moles/mg protein) in
MDR-negative (MES-SA, K562) and MDR-positive
(Dxi K562/R7) Human Cancer Cells
Treatment

PUT

SPD
SPM
MES SA

PUT

SPD

5PM

caused a 60-fold decrease in the MDR-positive DX5 line.

DX5

Similarly, while the baseline vinblastine content in DX5

-

20 cells was, as expected, less than in MES-SA cells, the

Control

2172 11913

6477

1195

9685

6202

conjugate increased drug retention in the MDR-negative

DFMO (1 mM)

ND

6100

8824

ND

4191

6831

cells by a mere 50% while vinblastine retention was

6845

4368

ND

7496

6089

Poly-SPM

722

(20 PM)
PQIY-SPM +
DFMO

ND

gggglu mM)

5133131 @913? 12321 61?? @333 gig?

PO1y_SPM
(20 11M)
ggégpM +

ND

3234

2384

1042

6133

4779

ND

2412

2312

ND

2142

1793

3477
K562

4167

ND

_

_

_ _

_

mcreased over 200% in the MDR-positive line. These ?nd
ings provide pharmacologic evidence that the MDR pathway
25 and polyarnine transport are functionally interactive in this

5136
5635
16mm

human uterine sarcoma cell line. Similar results were gen

erated with the use of another substrate of MDR transporter,
Taxol. Treatment with 100 M poly-SPM increased the
30 accumulation of Taxol in DX5 cells, but not MES-SA.
Poly-SPM also caused a decrease in IC50 for Taxol in DX5

without signi?cant effect on MDR-negative MES-SA cell
line (data not shown).
TABLE 9
Impact of Poly-PUT Conjugate on vinblastine Cytotoxicity

and Uptake by MDR-negative (MES-SA) and MDR<positive (DX5)
Human Uterine Sarcoma Cells

1“C-Vinblastrine Content

IC50 (11M)

(dpm/30/min/ug protein)

Cell Line

Control

+100 11M PUT-Conjugate

Control

+100 uM PUT—Conjugate

MES-SA
DX5

.005
0.6

.007
.116

6.2 i 0.6
3.2 i 0.7

8.3 i 0.7
8.3 i 1.3

Collectively, these ?ndings indicate that the cytotoxicity

EXAMPLE 12

of polyarnine conjugates in human tumor cells is associated

with depressed transmembrane polyamine transport and
decreased cell polyamine contents. It is therefore reasonable
to conclude that the decreased cell polyarnine content is the

50

Effect of DFMO on Polyamine Transport in

MDR-negative (MES-SA) and MDR-positive
(DX5) Human Uterine Sarcoma Cells

proximate mechanism of cytotoxic action of the polyamine
conjugates. We also have observed interesting di?’erences in
the impact of polyarnine transport blockade and kinetics of

In many cells, DFMO increases polyarnine transport. This

polyarnine transport between MDR-positive and -negative

is believed to be a compensatory mechanism that protects

cell lines, which suggest that there exist pharrnacologically
signi?cant interactions between these transport systems.

liminary studies described supra, DFMO was less e?ective

these cells from polyamine depletion. Indeed, in the pre

than transport blockade in reducing cell polyamines and in

EXAMPLE ll

Modulation of MDR Activity by Polyamine
Transport and Synthesis Inhibition in Human
Uterine Sarcoma Cells

Complimentary experiments were conducted to determine

whether the polyarnine uptake inhibitors differentially
affected the cytotoxicity and cellular uptake of vinblastine in
MDR-negative and MDR-positive uterine sarcoma cells.
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causing cell death. The present invention accordingly con
cluded that the induction of transport by DFMO would be a
useful strategy for further experiments. Indeed, if MDR
activity is linked to polyamine transport rate, then the
actions of DFMO on MDR activity should be opposite to
those of the transport inhibitors, despite the fact that both
DFMO and the transport inhibitors have qualitatively similar
effects on cell polyamine contents. In other words, while

polyaminc conjugates decrease MDR activity, DFMO

5,456,908
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should promote an increase in activity which reduces cyto

What is claimed is:
1. A method for inhibiting the cellular uptake of a

toxic drug content and decreases drug-induced lethality. We
therefore examined the impact of DFMO on polyamine

polyamine or polyamines comprising contacting cells which
are capable of actively transporting said polyamine or

transport rate and on vinblastine accumulation and cytotox

icity in MES-SA and DX5 cells. As shown in Table 10, it

polyamines with a transport inhibitory e?iective amount of

was found that 24 hours’ treatment with DFMO caused

slight increases in both PUT and SPD transport rate in DX5
cells but, surprisingly, not in MES-SA cells. These results
suggest that cells expressing the MDR phenotype exhibit a
DEMO-inducible polyamine transporter that may not be

an inhibitor which comprises a polymer or copolymer

wherein the repeating units comprise said polyamine or

polyamines.
10

present in MDR-negative cells.

2. The method of claim 1 wherein the repeating units of
the transported substance are covalently attached by a cou

pling agent.
TABLE 10

3. The method of claim 2 wherein the coupling agent is

E?tect of DFMO on Polyamine Transport in MDR-negative
(MES-SA) and MDR-positive (DX5) Human Uterine

glutaraldehyde.
15

Sarcoma Cells

4. The method of claim 1 wherein said polymer or

copolymer comprises a polyamine selected from the group

consisting of putrescine, spermine and spermidine.

1“ C-Polyamine uptake (pmoles/rnin/mg protein)

5. The method of claim 1 wherein said polymer of the
CONTROL

transported substance comprises a molecular weight ranging

PUT

from 15,000 to 100,000 daltons.
6. The method of claim 1 wherein the polymer of the
transported substance is further attached to a moiety which
provides for the selective targeting of the inhibitor to cells

DFMO (1 mM)

Cell Line

SPD

SPD

PUT

MES-SA
DX5

0.7 i 0.06
0.8 i 0.05

7.6 i 0.2
1.4 i 0.2

0.67 i 0.01
1.1 i 0.04

7.3 i .06
1.6 i .08
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which uptake the transported substance.
7. The method of claim 4 wherein said copolymer com

prises different polyamines.
8. The method of claim 4 wherein the molecular weight of

EXAMPLE 13

said polyamine polymer ranges from about 15,000 to 100,
Eifect of DFMO on Vinblastine Accumulations in

30

MDR~negative (MES-SA) and MDR-positive
(DX5) Human Uterine Sarcoma Cells
DFMO, as predicted, decreased vinblastine accumulation
in DX5 cells but not in the parental line, MES-SA (Table 11).
In a companion study, MES-SA cells exhibited the expected
sensitivity to vinblastine relative to DX5, characterized by

35

polyamines.
11. The method of claim 10 wherein said substance is

IC50 values of 0.005 M and 0.5 M, respectively. Impor
tantly, DFMO treatment failed to affect the IC5o value for
vinblastine in MES-SA cells but engendered complete resis

000 daltons.
9. The method of claim 4 wherein the treated cells
comprise tumor cells or pulmonary artery smooth muscle
cells.
10. The method of claim 9 wherein said cells are further
contacted with a substance which inhibits the synthesis of

d-di?uoro-methylomithine.
40

tance in DX5 cells to vinblastine, at least in concentrations

12. The method of claim 9 wherein said cells comprise
tumor cells which are further contacted with an anti-tumor

agent, and the e?icacy of said anti-tumor agent is assessed

up to 5 uM. Thus, DFMO which increases polyamine
transport in DX5 cells also appears to increase MDR activity

in relation to control tumor cells which are contacted with
said anti-tumor agent but which cells are not contacted with

and render MDR-positive cells even more resistant to the

cytotoxic eifects of vinblastine.

the inhibitor.
13. The method of claim 1 wherein said contacting is

TABLE 11

effected in vitro in a cell culture medium which contains

cells which are capable of uptaking said polyamine or

E?’ect of DPMO on Vinblastine Accumulation in MDR-negative

polyamines by active transport.

(MES-SA) and MDR-positive (DX5) Human Uterine
Sarcoma Cells

3I-I-Virtblastine Content (pmoles/mg protein)
Cell Line

CONTROL

DFMO (1 mM)

MES-SA
DX5

825 i 20
290 i 10

840 i 28
195 i 8
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14. The method of claim 13 wherein said cells are human
tumor cells.

15. The method of claim 10 wherein the polyamine
synthesis inhibiting substance is a substance which inhibits

omithine decarboxylase.
55

